Impel Pharmaceuticals Inc
IMPL
Get informed when a big investor buys or sells
+ FollowMarket Cap$956K
Close$
Share Statistics
| Market cap | $956,000.00 |
|---|---|
| Enterprise Value | $115.52 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.52 |
| Beta | 1.17 |
| Outstanding Shares | 23,749,005 |
Return
| Return on Equity | 90.14% |
|---|---|
| Return on Assets | -236.20% |
| Return on Invested Capital | 78.83% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0.01 |
| Price to Sales | - |
| Price to Book Ratio | -0.01 |
| Enterprise Value to Revenue | 5.5 |
| Enterprise Value to EBIT | -1.63 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.99 |
| Debt to Equity | -1.25 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Impel NeuroPharma Inc.
59 employees
CEO: Michael Hite Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initia...